Pharmaceutical Biotechnology Glossary

A small, non-enveloped virus commonly used as a vector for gene therapy due to its low pathogenicity and ability to infect both dividing and non-dividing cells.

A targeted therapy combining a monoclonal antibody linked to a cytotoxic drug payload via a chemical linker for selective delivery to antigen-expressing cells.

The fraction of an administered dose of drug that reaches the systemic circulation in an unchanged form. For biologics administered subcutaneously, bioavailability typically ranges from 50-80%.

A controlled vessel for growing cells or organisms to produce biopharmaceutical products, with regulation of temperature, pH, dissolved oxygen, and nutrient supply.

A biologic product demonstrated to be highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency.

A personalized immunotherapy in which a patient's T cells are engineered to express a chimeric antigen receptor targeting a specific tumor antigen, then reinfused to attack cancer cells.

Chinese Hamster Ovary cells, the most widely used mammalian cell line for large-scale industrial production of recombinant therapeutic proteins, particularly monoclonal antibodies.

A genome editing system using a guide RNA to direct the Cas9 endonuclease to a specific genomic locus, enabling precise gene knockout, correction, or insertion.

A physical, chemical, biological, or microbiological property that should be within an appropriate limit to ensure the desired product quality of a biopharmaceutical.

The purification and formulation stages of biopharmaceutical manufacturing following cell culture, including chromatography, filtration, viral clearance, and fill-finish operations.

A DNA construct (plasmid or viral genome) designed to carry and express a gene of interest in a host cell, containing promoters, selection markers, and other regulatory elements.

The crystallizable fragment of an antibody that interacts with cell surface receptors and complement proteins, mediating effector functions and determining serum half-life through FcRn binding.

The enzymatic post-translational modification that attaches oligosaccharide chains to proteins, critically affecting folding, stability, function, and immunogenicity of biopharmaceuticals.

Regulatory guidelines ensuring that pharmaceutical products are consistently produced and controlled according to quality standards, covering all aspects from raw materials to final product release.

The propensity of a therapeutic protein to generate an immune response, including anti-drug antibodies, which can affect drug efficacy, pharmacokinetics, or patient safety.

A nanoscale delivery system composed of ionizable lipids, structural lipids, cholesterol, and PEG-lipids, used to encapsulate and deliver nucleic acids such as mRNA into cells.

An antibody produced by a single clone of B cells, resulting in a homogeneous population of identical antibodies with specificity for a single epitope on a target antigen.

Biopharmaceuticals using synthetic messenger RNA to instruct cells to produce specific therapeutic or antigenic proteins, encapsulated in delivery vehicles such as lipid nanoparticles.

The covalent attachment of polyethylene glycol polymer chains to a therapeutic molecule to increase its hydrodynamic size, reduce renal clearance, and extend its circulating half-life.

The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems, especially important for biologics due to immunogenicity risks.

An affinity purification technique using immobilized Protein A to selectively bind the Fc region of IgG antibodies, serving as the primary capture step in monoclonal antibody manufacturing.

A protein produced by a host cell that has been genetically engineered to carry the gene encoding the protein of interest, enabling large-scale production of human therapeutic proteins.

The initial phase of biopharmaceutical manufacturing encompassing cell line development, media preparation, cell expansion, and production-scale bioreactor cultivation.

Manufacturing process steps specifically designed to remove or inactivate potential viral contaminants in biopharmaceutical production, including low-pH treatment, nanofiltration, and chromatographic methods.

A modified virus used to deliver genetic material into cells for gene therapy. The viral genes responsible for replication and pathogenicity are removed and replaced with the therapeutic gene.